Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer

BACKGROUNDS: Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer. Because paclitaxel-resistant cancer shows hi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Med Oncol
Hauptverfasser: Shin, Sol-Bi, Woo, Sang-Uk, Yim, Hyungshin
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2019
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6515847/
https://ncbi.nlm.nih.gov/pubmed/31156720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919846375
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge